REFERENCE
Rutten-van Mölken MPMH, Van Nooten FE, Lindemann M, Caeser M, Calverley PMA.A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease. PharmacoEconomics 25: 695-711, No. 8, 2007
Rights and permissions
About this article
Cite this article
Roflumilast of value in very severe COPD. Pharmacoecon. Outcomes News 535, 10 (2007). https://doi.org/10.2165/00151234-200705350-00023
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705350-00023